Skip to main content
 
Print Page    E-mail Page    RSS    E-mail Alerts    Tearsheet 

Investors & Media

Corporate Profile

Seres Therapeutics, Inc. is a microbiome therapeutics platform company developing a novel class of biological drugs, which we refer to as Ecobiotic microbiome therapeutics, that are designed to restore health by repairing the function of a dysbiotic microbiome. The Company’s lead product candidate, SER-109, is intended to prevent further recurrences of Clostridium difficile infection (CDI), a debilitating infection of the colon, and, if approved by the FDA, could be a first-in-field drug. Using its... More

Recent NewsMore
11/14/17
Seres Therapeutics, MD Anderson Cancer Center, and the Parker Institute for Cancer Immunotherapy Announce a Collaboration to Support the Investigation of Microbiome Therapeutics for Immuno-Oncology
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Nov. 14, 2017-- Seres Therapeutics, Inc. (NASDAQ:MCRB), The University of Texas MD Anderson Cancer Center (MD Anderson), and the Parker Institute for Cancer Immunotherapy (Parker Institute) today announced a collaboration to evaluate the potential of Seres’ microbiome therapies to improve the outcomes of cancer patients treated with currently-available immunotherapy. This press release features multimedi... 
11/08/17
Seres Therapeutics to Participate in Three Upcoming November Conferences
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Nov. 8, 2017-- Seres Therapeutics, Inc., (NASDAQ:MCRB) today announced that it will participate in each of the following upcoming healthcare conferences: Stifel 2017 Healthcare Conference: A corporate overview will be presented on Tuesday, November 14 at 5:00 p.m. ET in New York, NY. 29th Annual Piper Jaffray Healthcare Conference: A corporate overview will be presented on ... 
11/08/17
Seres Therapeutics Reports Third Quarter 2017 Financial Results and Provides Update on Operational Progress
– Positive results from SER-287 Phase 1b study in mild-to-moderate Ulcerative Colitis; Company to move program into further development – – Company awarded CARB-X grant to advance SER-155 for allogeneic stem cell and solid organ transplantation – – Conference call at 8:00 a.m. ET today – CAMBRIDGE, Mass.--(BUSINESS WIRE)--Nov. 8, 2017-- Seres Therapeutics, Inc.,(NASDAQ:MCRB) today reported third quarter 2017 financial re... 
EventsMore
Webcast ImageWebcast
Seres Therapeutics, Inc. at the Stifel 2017 Healthcare Conference (Replay)
11/14/17 at 5:00 p.m. ET
Seres Therapeutics, Inc. at the Stifel 2017 Healthcare Conference
Tuesday, November 14, 2017 5:00 p.m. ET  
Webcast PresentationHelp Help
Click here for webcast
Add to CalendarHelp Help
Add to Calendar Click here to add this event to your calendar
Download DocumentationCorporate Presentation

There are currently no upcoming events scheduled.
Stock Quote
NASDAQ:MCRB
$9.37
 - 0.01 (0.11%)
11/21/17 2:06 p.m. ET
Refresh quote
E-mail Alerts
Sign up to receive e-mail alerts whenever Seres Therapeutics, Inc. posts new information to the site. Just enter your e-mail address and click Submit.
Request Information

Obtain investor relations information by contacting us.

More
Data provided by Nasdaq. Minimum 15 minutes delayed.